Literature DB >> 9439551

The stimulation of insulin secretion in non-insulin-dependent diabetic patients by amino acids and gliclazide in the basal and hyperglycemic state.

D R Matthews1, O Boland.   

Abstract

Sulfonylureas stimulate insulin secretion as their predominant contribution toward decreasing blood glucose in diabetic patients. We studied eight gliclazide-treated, non-insulin-dependent diabetic patients on two occasions with a protocol of basal observation for 30 minutes, a 60-minute infusion of randomized leucine or arginine, and a further 90-minute hyperglycemic clamp. Basal glucose was the same on both occasions (mean, 7.82 mmol/L for leucine v 7.79 for arginine, P = NS), and glucose levels declined to 7.50 and 7.25 mmol/L, respectively, by 30 minutes. After leucine infusion, the decline of glucose continued, but stabilized or reversed with arginine such that by the end of the infusions, glucose levels were 6.63 +/- 0.69 mmol/L for leucine and 7.62 +/- 0.67 for arginine (P < .02). Arginine caused a sharp increase in insulin secretion (from 17.8 mU/L to 43.8 mU/L in 6 minutes) at the onset of the infusion, and thereafter insulin secretion was not significantly different throughout either the amino acid or hyperglycemic clamp periods (mean, 42.1 v 44.7 mU/L, respectively, P = NS). By contrast, the leucine infusion caused little acute change in secretion, but augmented it with time from the basal period (17.2 mU/L) to the end of the infusion (29.4 mU/L). During the hyperglycemic clamp period, there was significant further augmentation of insulin secretion, increasing to 81.6 +/- 16 mU/L at the end of the study. Leucine significantly augmented insulin secretion compared with arginine (81.6 +/- 16 v 54.0 +/- 8.4 mU/L, respectively, P < .002). These data suggest that leucine is a better priming agent for sulfonylurea than arginine. Additive effects on insulin secretion may allow the use of combinations of branched chain amino acids (BCAAs) and sulfonylureas to augment insulin secretion in the presence of hyperglycemia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9439551     DOI: 10.1016/s0026-0495(97)90309-7

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  4 in total

Review 1.  Macronutrient Composition and Management of Non-Insulin-Dependent Diabetes Mellitus (NIDDM): A New Paradigm for Individualized Nutritional Therapy in Diabetes Patients.

Authors:  Efi Koloverou; Demosthenes B Panagiotakos
Journal:  Rev Diabet Stud       Date:  2016-05-10

2.  Protein acetylation derepresses Serotonin Synthesis to potentiate Pancreatic Beta-Cell Function through HDAC1-PKA-Tph1 signaling.

Authors:  Yuqing Zhang; Shushu Wang; Linlin Zhang; Feiye Zhou; Kecheng Zhu; Qin Zhu; Qianqian Liu; Yun Liu; Lei Jiang; Guang Ning; Yufang Bi; Libin Zhou; Xiao Wang
Journal:  Theranostics       Date:  2020-06-05       Impact factor: 11.556

3.  Branched-chain amino acid supplementation for improving growth and development in term and preterm neonates.

Authors:  Shoichiro Amari; Sadequa Shahrook; Fumihiko Namba; Erika Ota; Rintaro Mori
Journal:  Cochrane Database Syst Rev       Date:  2020-10-02

4.  Structural basis for amino acid transport by the CAT family of SLC7 transporters.

Authors:  Katharina E J Jungnickel; Joanne L Parker; Simon Newstead
Journal:  Nat Commun       Date:  2018-02-07       Impact factor: 14.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.